Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14658931 | 0.99 | TRPV1 (0.49) | TRPV1MAPK14 | |
| SCHEMBL14661976 | 0.87 | TRPV1 (0.51) | TRPV1 | |
| SCHEMBL12982424 | 0.85 | TRPV1 (0.37) | TRPV1MAPK14 | |
| SCHEMBL12982712 | 0.84 | MAPK14 (0.50) | TRPV1MAPK14 | |
| SCHEMBL12981572 | 0.84 | TRPV1 (0.48) | TRPV1MAPK14 | |
| SCHEMBL287951 | 0.84 | GRN (0.55) | TRPV1MAPK14 | |
| SCHEMBL12982664 | 0.84 | TRPV1 (0.52) | TRPV1MAPK14 | |
| SCHEMBL287455 | 0.83 | TRPV1 (0.57) | TRPV1MAPK14 | |
| SCHEMBL12983350 | 0.83 | TRPV1 (0.43) | TRPV1MAPK14 | |
| SCHEMBL12982945 | 0.82 | MAPK14 (0.51) | TRPV1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2776398-B1 | SUBSTITUTED PYRAZOLYL-BASED UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | MEDIFRON DBT INC (KR) | 2020-09-02 | — | — | EP | disclosed |
| US-9624209-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2017-04-18 | — | — | US | disclosed |
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | MEDIFRON DBT INC. (KR) | 2015-04-09 | — | — | US | disclosed |
| US-8946204-B2 | Substituted phenylureas and phenylamides as vanilloid receptor ligands | GRUENENTHAL GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2776399-A1 | SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN N-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2014-09-17 | — | — | EP | disclosed |
| EP-2776398-A1 | SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN O-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2014-09-17 | — | — | EP | disclosed |
| EP-2638015-A1 | SUBSTITUTED BICYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| EP-2638034-A1 | SUBSTITUTED HETEROAROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| WO-2013068461-A1 | SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN O-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013068462-A1 | SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN N-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-05-16 | — | — | WO | disclosed |
| US-20130029962-A1 | Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| US-20130029962-A1 | Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2013-01-31 | — | — | US | disclosed |
| WO-2013013815-A1 | SUBSTITUTED HETEROAROMATIC PYRAZOLE-CONTAINING CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2013-01-31 | — | — | WO | disclosed |
| US-20120258946-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-10-11 | — | — | US | disclosed |
| WO-2012062463-A1 | SUBSTITUTED BICYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012062462-A1 | SUBSTITUTED HETEROAROMATIC CARBOXAMIDE AND UREA DERIVATIVES AS VANILLOID RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115903-A1 | Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | GRUENENTHAL GMBH (DE) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099728-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | TRPV1 1/4885MAPK14 1748/4885 |
| US-20120115903-A1 | Substituted Heteroaromatic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | TRPV1, OPRM1, OPRK1 | TRPV1 1/4885MAPK14 2243/4885 |
| US-20120258946-A1 | Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands | TRPV1, TRPV5, TRPV6 | TRPV1 1/4885MAPK14 1748/4885 |
| US-20130029962-A1 | Substituted Heteroaromatic Pyrazole-Containing Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | TRPV1, GPR17, TRPV3 | TRPV1 1/4885MAPK14 1098/4885 |
| US-20120115893-A1 | Substituted Bicyclic Carboxamide and Urea Compounds as Vanilloid Receptor Ligands | TRPV1, CNR1, CNR2 | TRPV1 1/4885MAPK14 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.